The U.S. FDA assigned a target action date of April 8, 2026PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #FDA--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA ...

The only thing more awkward than forgetting your kid? Finding him Home Alone with two corpses.

Abstract: As a promising alternative for minimally invasive vascular surgery, robot-assisted vascular interventional system (VIS) has expressed considerable benefits in preventing radiation, ...

Ms. Ishak brings more than 25 years of corporate legal and strategic leadership experience in the life sciences industry ...

Coherus Oncology, Inc. (NASDAQ: CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) plus ...

Objective Delivery of a small for gestational age (SGA) infant is a common pregnancy complication among women with SLE.

AstraZeneca advances its ambition to redefine hematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, ...

Over the past two decades, thoracic oncology has undergone a profound transformation, moving from limited chemotherapy ...

Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality worldwide.1 Despite therapeutic ...

Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial ...

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of more than 95 data disclosures, including 27 oral presentations, across company-sponsored studies and external collaborations at the ...

Wearable/implantable phototherapy devices offer advantages such as portability, ease of use, and personalized treatment. This ...